Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18526789 | 1.00 | POLB (0.32) | POLBEPHX2PYGLCYP2C9TSHR | |
| SCHEMBL754126 | 0.87 | PYGL (0.40) | EPHX2PYGLCYP2C9SMN1; SMN2 | |
| SCHEMBL18526639 | 0.87 | PYGL (0.40) | EPHX2PYGLCYP2C9SMN1; SMN2 | |
| SCHEMBL10174960 | 0.87 | CA12 (0.40) | CA14 | |
| SCHEMBL15823887 | 0.87 | CA12 (0.40) | CA14 | |
| SCHEMBL12900573 | 0.83 | EPHX2 (0.33) | POLBEPHX2PYGLCYP2C9SMN1; SMN2 | |
| SCHEMBL14979937 | 0.81 | THRB (0.41) | TSHRSMN1; SMN2THRB | |
| SCHEMBL10211896 | 0.80 | MMP13 (0.39) | POLBPYGLCYP2C9TSHRSMN1; SMN2 | |
| SCHEMBL18901902 | 0.80 | MMP13 (0.39) | POLBPYGLCYP2C9TSHRSMN1; SMN2 | |
| SCHEMBL754130 | 0.79 | CYP3A4 (0.51) | POLBCYP2C9TSHRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | BRISTOL MYERS SQUIBB CO (US) | 2017-12-14 | — | — | US | disclosed |
| EP-2601188-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-10-18 | — | — | EP | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-9776981-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2513091-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-04-12 | — | — | EP | disclosed |
| EP-2499132-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2499115-B1 | PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) | 2016-07-27 | — | — | EP | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303007-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-04-05 | — | — | US | disclosed |
| WO-2010138368-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010120621-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010117704-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| WO-2010117977-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-10-14 | — | — | WO | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-10-14 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355689-A1 | HEPATITIS C VIRUS INHIBITOR | HAVCR2, LIPC, PYGL | POLB 1352/4885EPHX2 2180/4885PYGL 3/4885 |
| US-20100215616-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | POLB 1431/4885EPHX2 2195/4885PYGL 2/4885 |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | POLB 2384/4885EPHX2 3519/4885PYGL 27/4885 |
| US-20100260708-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | POLB 1431/4885EPHX2 2195/4885PYGL 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.